Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952356 | 0.85 | RXFP1 (0.41) | F2RALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL16706941 | 0.81 | PTPN1 (0.50) | CTNNB1WNT3AALDH1A1HPGDHSD17B10 | |
| SCHEMBL5309095 | 0.81 | CTNNB1 (0.46) | F2RCTNNB1WNT3AALDH1A1HPGD | |
| SCHEMBL3346960 | 0.81 | CTNNB1 (0.58) | F2RCTNNB1WNT3AALDH1A1HPGD | |
| SCHEMBL2475812 | 0.81 | F2R (0.43) | F2RALDH1A1HPGDALOX15TSHR | |
| SCHEMBL6744512 | 0.81 | ALDH1A1 (0.48) | F2RCTNNB1WNT3AALDH1A1HPGD | |
| SCHEMBL9116089 | 0.79 | F2R (0.42) | F2RCTNNB1WNT3AALDH1A1HPGD | |
| SCHEMBL6744189 | 0.78 | HDAC8 (0.48) | CTNNB1WNT3A | |
| SCHEMBL11566666 | 0.77 | SMN1; SMN2 (0.50) | CTNNB1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL2336667 | 0.76 | F2R (0.51) | F2RALDH1A1HPGDALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374788-A1 | INDANYL COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | F2R 651/4885CTNNB1 1740/4885WNT3A 2325/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | F2R 465/4885CTNNB1 892/4885WNT3A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.